Trial Profile
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 May 2023
Price :
$35
*
At a glance
- Drugs Daratumumab/hyaluronidase (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics
- Acronyms PAVO
- Sponsors Janssen Research & Development
- 04 May 2023 Status changed from active, no longer recruiting to completed.
- 14 Mar 2023 Planned End Date changed from 28 Feb 2023 to 3 Apr 2023.
- 20 Dec 2022 Planned End Date changed from 30 Nov 2022 to 28 Feb 2023.